VERICEL CORPORATION Deferred Revenue
VERICEL CORPORATION (VCEL) had Deferred Revenue of $503.00 thousand as of 2018-06-30, per its 10-Q filed 2018-08-06.
Discontinued › Balance Sheet › Liabilities › Liabilities, Current › Deferred Revenue, Current
us-gaap:DeferredRevenueCurrent · last filed 2018-08-06
- 2018-06-30: Deferred Revenue, Current $503.00K.
- 2018-03-31: Deferred Revenue, Current $426.00K.
- 2017-12-31: Deferred Revenue, Current $420.00K.
- 2017-09-30: Deferred Revenue, Current $506.00K.
| Period end | Deferred Revenue, Current |
|---|---|
| 2018-06-30 | $503.00K 10-Q · filed 2018-08-06 |
| 2018-03-31 | $426.00K 10-Q · filed 2018-05-08 |
| 2017-12-31 | $420.00K 10-Q · filed 2018-08-06 |
| 2017-09-30 | $506.00K 10-Q · filed 2017-11-07 |
| 2017-06-30 | $515.00K 10-Q · filed 2017-08-09 |
| 2017-03-31 | $397.00K 10-Q · filed 2017-05-10 |
| 2016-12-31 | $0.00 10-Q · filed 2017-11-07 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| RECURSION PHARMACEUTICALS, INC. (RXRX) | United States | $2.080B | -3.78 |
| Kodiak Sciences Inc. (KOD) | United States | $2.090B | -10.12 |
| ADMA BIOLOGICS, INC. (ADMA) | United States | $2.131B | 11.16 |
| BIOCRYST PHARMACEUTICALS INC (BCRX) | United States | $2.175B | -6.63 |
| Vir Biotechnology, Inc. (VIR) | United States | $1.814B | -6.85 |
| NOVAVAX INC (NVAX) | United States | $1.748B | -6.26 |
| Hemab Therapeutics Holdings, Inc. (COAG) | United States | $1.672B | |
| Greenland Mines Ltd (GRML) | United States | $2.362B | |
| Immunocore Holdings plc (IMCR) | $1.613B | -90.43 | |
| Taysha Gene Therapies, Inc. (TSHA) | United States | $1.564B | -14.80 |